This biotech company is a standout in its sector, with impressive upside potential. Here’s why we’re watching Halozyme Therapeutics (NASDAQ: HALO).

Zurich-based startup Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

The Fed’s interest rate pause, closed capital markets, the tariff storm, and mass layoffs at the U.S. FDA create a ...

Thermo Fisher Scientific reported better-than-expected profit and revenue for the first quarter on Wednesday, helped by ...

Find out how you can mitigate risks when expanding your biotech business internationally in the current tariff and trade ...

Dr Katerina Steventon talks healthy ageing, prevention, biotech and more with Dermalogica’s Dr Robert J Bianchini ...

BERLIN (Reuters) -Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 billion merger deal with a ...

Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that ...

Switzerland's Xlife Sciences AG said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition in a deal that will value the combined company at $1.64 billion.